EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of robenidine analogue NCL195 against methicillin-resistant Staphylococcus pseudintermedius

Sayara Bista iD, Hang Thi Nguyen, Tatiana P Soares da Costa, Lucy Woolford, Mark A T Blaskovich, Tania Veltman, Kelly A Young, Adam McCluskey, Meng Siak, Stephen W Page, Henrietta Venter iD, Darren J Trott und 1 weitere

Microbiology Spectrum · 02.06.2026 · 14 (6)

DOI: 10.1128/spectrum.03187-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 02.06.2026. Verfasst von Sayara Bista und 12 weiteren Autor:innen. Beteiligte Einrichtung: ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance, The University of Queensland, Brisbane, Queensland, Aus…. Hauptthemen laut MEDLINE: Robenidine, Staphylococcus, Methicillin Resistance, Staphylococcal Infections. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Education and Training | Australian Research Council (ARC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rise of difficult-to-treat infections among companion animals, particularly the increasing incidence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) in dogs poses significant challenges for effective treatment options in veterinary practice. In this study, we demonstrate that the novel robenidine analog NCL195 exhibits antibacterial activity against MRSP isolates collected from dogs, achieving uniform minimal inhibitory concentrations of 1 μg/mL across all 160 isolates from multiple clinical cases and representing diverse sequence types. NCL195 acts by disrupting the bacterial cell membrane potential; no resistant mutants emerged during prolonged serial passage experiments, and transmission electron microscopy showed marked changes to the cell membrane of NCL195-treated MRSP compared to untreated controls. Furthermore, NCL195 showed minimal lysis of dog and sheep red blood cells and moderate toxicity to mammalian cell lines. These results highlight NCL195 as a promising candidate for further development as a novel antimicrobial agent to address the urgent need for effective treatments against MRSP infections in veterinary medicine. IMPORTANCE The rise of difficult-to-treat infections among companion animals, particularly the increasing incidence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) in dogs, poses significant challenges for effective treatment options in veterinary practice. Here, we show that NCL195, a member of a novel class of pyrimidine compounds, exhibits antibacterial activity against 160 MRSP isolates collected from dogs from multiple clinical cases. Additionally, no resistant mutants developed during prolonged serial passage experiments, and NCL195 showed low lysis of dog and sheep red blood cells. Developing NCL195 as an “animal-only” drug promotes the “responsibility” and “refinement” principles of antimicrobial stewardship.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RobenidineStaphylococcusMethicillin ResistanceStaphylococcal InfectionsAnimalsDogsDrug Resistance, BacterialCell MembraneCell LineSheepErythrocytesVero CellsChlorocebus aethiopsHumans

Stichwörter der Autor:innen

antimicrobial agentsantimicrobial stewardshipbactericidal activitycell toxicityhaemolysismethicillin-resistant Staphylococcus pseudintermediusminimal inhibitory concentrationsmultidrug resistancerobenidinetransmission electron microscopy

Substanzen

Robenidine

Autor:innen und Institutionen

  • ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance, The University of Queensland, Brisbane, Queensland, Australia.
  • Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, Australia.
  • School of Agriculture, Food and Wine & Waite Research Institute, The University of Adelaide, Urrbrae, South Australia, Australia.
  • School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, Australia.
  • Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
  • Chemistry, School of Environmental and Life Sciences, The University of Newcastle, Callaghan, New South Wales, Australia.

ORCID-Profile: Sayara Bista, Henrietta Venter, Abiodun D Ogunniyi

Förderung

  • Department of Education and Training | Australian Research Council (ARC)

Zitieren

APA

Bista, S., Nguyen, H. T., Soares da Costa, T. P., Woolford, L., Blaskovich, M. A. T., Veltman, T., Young, K. A., McCluskey, A., Siak, M., Page, S. W., Venter, H., Trott, D. J., & Ogunniyi, A. D. (2026). In vitro activity of robenidine analogue NCL195 against methicillin-resistant Staphylococcus pseudintermedius. Microbiology Spectrum, 14(6). https://doi.org/10.1128/spectrum.03187-25

Vancouver

Bista S, Nguyen HT, Soares da Costa TP, Woolford L, Blaskovich MAT, Veltman T, et al. In vitro activity of robenidine analogue NCL195 against methicillin-resistant Staphylococcus pseudintermedius. Microbiology Spectrum. 2026;14(6). doi:10.1128/spectrum.03187-25

BibTeX
@article{Bista2026,
  author = {Bista, Sayara and Nguyen, Hang Thi and Soares da Costa, Tatiana P and Woolford, Lucy and Blaskovich, Mark A T and Veltman, Tania and Young, Kelly A and McCluskey, Adam and Siak, Meng and Page, Stephen W and Venter, Henrietta and Trott, Darren J and Ogunniyi, Abiodun D},
  title = {In vitro activity of robenidine analogue NCL195 against methicillin-resistant Staphylococcus pseudintermedius},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {6},
  doi = {10.1128/spectrum.03187-25}
}
Kostenlos starten →